Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Clarus Ventures Information
Clarus Ventures was acquired by
Blackstone Group.
The acquisition happend on 2018-10-04.
Details of the transaction were not public
Acquirer
Geographic Data
Address:
City:
State:
Zip:
Country:
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Clarus Ventures is a life sciences venture capital firm founded by a team of accomplished investment professionals with extensive and complementary industry backgrounds which have enabled them to establish a long history of success in creating value. Their deep relationships with world thought leaders and decision makers allow this team to identify unique investment opportunities and shepherd them to maturity. Clarus augments its core expertise of investing in biopharmaceuticals and medical technology companies with the deep and diverse expertise of the team in research and development, commercialization, business development and operations management at the global level. Clarus has $1.2 billion of assets under management across two lifesciences dedicated funds
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 5/2013 | NanoString Technologies | Venture Round | 150k |
| 4/2013 | SFJ Pharmaceuticals | Private Equity Round | 13M |
| 11/2014 | Restoration Robotics | Series C | 45M |
| 12/2010 | TYRX | Venture Round | 20M |
| 12/2007 | Pelikan Technologies | Series F | 69M |
| 4/2013 | Pearl Therapeutics | Venture Round | 41.7M |
| 9/2007 | Pearl Therapeutics | Series A | 15.5M |
| 11/2012 | Pearl Therapeutics | Series D | 65M |
| 12/2006 | SARcode Bioscience | Venture Round | 29M |
| 8/2007 | Globus Medical | Series E | 110M |
| 2/2013 | Astria Therapeutics | Venture Round | 9M |
| 7/2010 | Zogenix | Venture Round | 0 |
| 12/2010 | Astria Therapeutics | Series A | 14.5M |
| 2/2010 | NanoString Technologies | Venture Round | 15M |
| 8/2011 | Restoration Robotics | Series C | 41M |
| 2/2007 | Proacta | Series B | 35M |
| 12/2012 | NanoString Technologies | Series E | 15.3M |
| 8/2010 | Achillion Pharmaceuticals | Post-IPO Equity | 50.1M |
| 6/2008 | CoMentis | Series D | 0 |
| 9/2006 | CoMentis | Series B | 50M |
| 10/2008 | Biolex Therapeutics | Series D | 0 |
| 4/2007 | Sientra | Series B | 85M |
| 3/2009 | SFJ Pharmaceuticals | Series A | 45M |
| 2/2009 | Heptares Therapeutics | Series A | 30M |
| 7/2015 | Nuvelution Pharma | Venture Round | - |
| 4/2009 | Aerovance | Venture Round | 38M |
| 1/2007 | SARcode Bioscience | Series A | 25M |
| 4/2012 | SFJ Pharmaceuticals | Private Equity Round | 35M |
| 7/2011 | SARcode Bioscience | Series B | 44M |
| 6/2012 | Oxford Immunotec | Equity | 28M |
| 1/2011 | TetraLogic Pharmaceuticals | Series C | 0 |
| 5/2009 | Lycera | Series A | 0 |
| 10/2012 | Pearl Therapeutics | Private Equity Round | 23.3M |
| 7/2008 | MacroGenics | Series D | 12.5M |
| 9/2010 | TetraLogic Pharmaceuticals | Series C | 5M |
| 1/2013 | Avillion | Venture Round | - |
| 1/2007 | VBI Vaccines | Series A | 35.7M |
| 8/2016 | Cleave Therapeutics | Series B | 0 |
| 10/2015 | Gritstone Bio | Series A | 102M |
| 10/2014 | Imago BioSciences | Series A | 26.5M |
| 11/2013 | Astria Therapeutics | Series B | 32.4M |
| 3/2012 | Sientra | Series C | 65M |
| 2/2016 | Forty Seven | Series A | 75M |
| 6/2016 | Flowonix | Debt Financing | 5M |
| 11/2014 | Flowonix | Venture Round | 20M |
| 7/2008 | Pearl Therapeutics | Series A | 18M |
| 11/2011 | Cleave Therapeutics | Series A | 42M |
| 7/2012 | SFJ Pharmaceuticals | Private Equity Round | 21M |
| 10/2013 | SFJ Pharmaceuticals | Venture Round | 30M |
| 10/2012 | SFJ Pharmaceuticals | Venture Round | 500k |
| 11/2011 | NanoString Technologies | Series D | 20M |
| 8/2010 | Taligen Therapeutics | Series B | 10M |
| 10/2007 | Oxford Immunotec | Series C | 0 |
| 2/2010 | Pearl Therapeutics | Series C | 15M |
| 4/2010 | Lycera | Series A | 11M |
| 5/2016 | GrayBug | Series B | 44.5M |
| 9/2018 | Galera Therapeutics | Series C | 70M |
| 3/2007 | Aerovance | Series C | 60M |
| 1/2008 | Taligen Therapeutics | Series B | 65M |
| 8/2006 | Zogenix | Series A | 60M |
| 1/2008 | Zogenix | Series B | 18M |
| 8/2016 | Avrobio | Series A | 25M |
| 2/2018 | Avrobio | Series B | 60M |
| 6/2016 | Annexon Biosciences | Series B | 44M |
| 6/2009 | NanoString Technologies | Series C | 30M |
| 12/2009 | IVERIC bio | Series B | 30M |
| 4/2010 | Astria Therapeutics | Series A | 39M |
| 1/2010 | Neomend | Series D | 30M |
| 12/2011 | Astria Therapeutics | Series A | 8M |
| 11/2009 | FerroKin Biosciences | Venture Round | 15M |
| 6/2010 | FerroKin Biosciences | Series B | 12M |
| 8/2010 | TetraLogic Pharmaceuticals | Series C | 0 |
| 8/2006 | ESBATech | Series B | 41M |
| 8/2008 | ESBATech | Series B | 22M |
| 6/2013 | Heptares Therapeutics | Series B | 0 |
| 11/2009 | Virdante Pharmaceuticals | Series A | 30M |
| 4/2016 | Lumos Pharma | Series B | 34M |
| 10/2017 | Forty Seven | Series B | 75M |
| 9/2017 | Gritstone Bio | Series B | 93M |
| 10/2009 | Zogenix | Series B | 36M |
| 5/2010 | Oxford Immunotec | Series D | 26M |
| 12/2014 | Annexon Biosciences | Series A | 34M |
| 4/2016 | Entasis Therapeutics | Series B | 50M |
| 1/2016 | ESSA Pharma | Post-IPO Equity | 15M |
| 3/2011 | Aerie Pharmaceuticals | Series B | 41.4M |
| 9/2008 | Link Medicine | Venture Round | 40M |
| 2/2017 | PATH | Venture Round | 25M |
| 9/2018 | Galera Therapeutics | Series C | 0 |
| 2/2018 | Avrobio | Series B | 0 |
| 10/2017 | Forty Seven | Series B | 0 |
| 9/2017 | Gritstone Bio | Series B | 0 |
| 2/2017 | PATH | Venture Round | 0 |
| 8/2016 | Cleave Therapeutics | Series B | 0 |
| 8/2016 | Avrobio | Series A | 0 |
| 6/2016 | Annexon Biosciences | Series B | 0 |
| 6/2016 | Flowonix | Debt Financing | 0 |
| 5/2016 | GrayBug | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
